Impli AG

Impli is a biotech company working on subdermal hormone monitoring platforms.

The first product identified for market launch as a medical device in 2027 in the U.S. will be for women undergoing IVF.

The device is expected to improve convenience for women who suffer from infertility by removing the need to have blood draws. Clinicians rely on blood draws to determine effective treatment interventions and this can in some cases require for bloods to be taken on a daily basis.

With Impli's electrochemical biosensor platform, specifically targeted biomarkers can be monitored to provide clinicians and patients with more data and better insights to improve patient outcome. The platform is implanted and removed after a normal 30 day IVF treatment cycle.